Clinical Trial Update: Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating green tea extract in patients with MGUS and/or smoldering multiple myeloma; the study was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Green Tea Extract (Camellia sinensis extract)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition | Phase 2 | Status: TERMINATED | Results posted: 2015-03-27